John Leonard, Intellia Therapeutics CEO

In­tel­lia plots Phase 3 study and a 2026 FDA sub­mis­sion af­ter CRISPR ther­a­py cuts swelling at­tacks by 98%

In­tel­lia Ther­a­peu­tics has re­vealed that a sin­gle in­fu­sion of its ex­per­i­men­tal CRISPR ther­a­py, called NT­LA-2002, al­most en­tire­ly elim­i­nat­ed swelling at­tacks in 10 peo­ple with hered­i­tary …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.